According to the approved antineoplastic targeted drugs, the mutational status of EGFR, KRAS, NRAS, BRAF, PIK3CA genes is routinely requested by the oncologist for the clinical management of patients with non-small cell lung carcinomas (NSCLC) [2–4], colorectal carcinomas (CRC) [5, 6], melanomas [7], breast carcinomas [8, 9]. This evidence concerns the gene KRAS and melanoma.